Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
You may also be interested in...
Korea’s Dong-A Pharmaceutical Inks JV To Build Plant In Mongolia
Struggling from a recent indictment of over rebates, Korea’s leading pharma seeks new momentum in one of the most sparsely populated countries in the world.
Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course
Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.
Korea’s Anti-Rebate Task Force Raids Dong-A Pharmaceutical
A South Korean task force aimed at rooting out illegal drug rebates, raided the head office of top domestic drug company Dong-A in which GlaxoSmithKline and Otsuka Pharmaceutical hold stakes.